Genzyme drug gets thumbs up from FDA panel

Sanofi's Genzyme unit won a key endorsement for mipomersen, an experimental therapy for homozygous familial hypercholesterolemia. But the tepid 9-6 vote from an FDA advisory panel left the new drug application looking relatively weak compared with a 13-2 vote for rival treatment lomitapide from Aegerion Pharmaceuticals ($AEGR). Report